Drug Safety

, Volume 10, Issue 2, pp 115–150 | Cite as

Clinical Toxicity of the Interferons

  • Thierry Vial
  • Jacques Descotes
Review Article Drug Experience


Since their initial description in 1957, the interferons (IFNs) have been increasingly used to treat a wide array of diseases. Acute adverse effects, i.e. ‘flu-like’ syndromes, hypo- or hypertension, tachycardia, headache, myalgias and gastrointestinal disorders, occur within the first hour or day after starting treatment. They are seldom treatment-limiting and are easily manageable.

Sub-acute and chronic effects develop after several days, usually within 2 and 4 weeks of therapy. The most typical is neurological toxicity, including fatigue/asthenia, and behavioural and cognitive changes. Such symptoms may seriously impair quality of life and result in treatment discontinuation. Seizures have seldom been described. Other infrequent central nervous system adverse effects include vertigo, cramp and oculomotor nerve paralysis. Distal paraesthesias and peripheral neuropathy have been reported.

IFN-associated autoimmunity is quite rare but a matter of concern. Biological or clinical manifestations usually require several months to become apparent. Autoantibodies have been shown to develop in most patients but have been inconsistently associated with clinical symptoms of systemic lupus erythematosus, rheumatoid-like arthritis and thyroiditis. Both hypo-and hyperthyroidism have been described but are usually reversible. Other infrequent autoimmune reactions include diabetes, pemphigus and worsening of multiple sclerosis. Although several patients present with a pre-existing autoimmune disorder, no predisposing factor has been clearly established.

While hypotension and tachycardia are the most frequent acute cardiovascular complications, a few additional cases of cardiac arrhythmias and myocardial ischaemia have been reported after a short course or several weeks of treatment. These latter complications do not appear to be dose-dependent or age-related. Isolated cases of congestive heart failure have also been described.

Mild proteinuria has been observed in 15 to 25% of patients, but acute renal toxicity is uncommon. A transient rise in serum aminotransferase levels is frequently noted during the first stage of therapy, especially in patients receiving the highest dosages. Direct hepatotoxicity is extremely rare. Autoimmune hepatitis, which is ill-diagnosed as chronic viral hepatitis, and de novo induction of autoimmune hepatitis, account for the majority of liver diseases.

Haematotoxicity is relatively common but mild to moderate, and develops gradually during the first weeks of treatment. Neutropenia is the most common haematological toxicity, but is usually not dose-limiting and resolves rapidly upon drug discontinuation. Myelosuppression, autoimmune and immune allergic haemolytic anaemias and thrombocytopenias have seldom been described.

Cutaneous adverse effects comprised nonspecific erythema and hair loss and, less frequently, vasculitis, local ulcerations at the site of injection and exacerbation of psoriasis.

Anti-IFN antibodies have been found with greatly varying incidence. The clinical consequences, e.g. loss of therapeutic activity, need to be further clarified. The appearance of anti-IFN antibodies should not lead to discontinuing treatment, but the use of another IFN preparation is required in patients with resistance.

Mild hormonal and metabolic disorders have been documented of which hypertriglyceridaemia is the more common. Clinically significant drug interactions have rarely been reported despite the potential inhibition of hepatic drug metabolism by IFN. The safety of IFN in pregnant women remains to be established.

Due to the more extensive use of IFNα, most adverse effects have been reported with IFNα preparations. Overall, the mechanisms underlying toxic effects are not well understood, and the incidence of adverse effects is usually dose- and duration-dependent.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abdi EA, Brien W, Venner PM. Auto-immune thrombocytopenia related to interferon therapy. Scandinavian Journal of Haematology 36: 515–519, 1986PubMedCrossRefGoogle Scholar
  2. Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 59: 896–900, 1987PubMedCrossRefGoogle Scholar
  3. Abrams PG, McClamrock E, Foon KA. Evening administration of alpha interferon. New England Journal of Medicine 312: 443–444, 1985PubMedCrossRefGoogle Scholar
  4. Adams F, Fernandez F, Marligit G. Interferon-induced organic mental disorders associated with unsuspected pre-exisiting neurologic abnormalities. Journal of Neuro-Oncology 6: 355–359, 1988PubMedCrossRefGoogle Scholar
  5. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. Journal of the American Medical Association 252: 938–941, 1984PubMedCrossRefGoogle Scholar
  6. Akard LP, Hoffman R, Elias L, Saiers JH. Alpha-interferon and immune hemolytic anemia. Annals of Internal Medicine 105: 306, 1986PubMedGoogle Scholar
  7. Alvarez JS, Sacristan JA, Alsar MJ. Interferon alpha-2a-induced impotence. Annals of Pharmacotherapy 25: 1397, 1991Google Scholar
  8. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 13: 364–371, 1991PubMedCrossRefGoogle Scholar
  9. Ansher SS, Puri RK, Thompson WC, Habig WH. The effects of interleukin 2 and alpha-interferon administration on hepatic drug metabolism in mice. Cancer Research 52: 262–266, 1992PubMedGoogle Scholar
  10. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. Journal of Infectious Diseases 163: 882–885, 1991PubMedCrossRefGoogle Scholar
  11. Antonelli G, Currenti M, Turriziani O, Riva E, Dianzani F. Relative frequency of nonneutralizing antibodies to interferon in hepatitis patients treated with different IFN-alpha preparations. Journal of Infectious Diseases 165: 593–594, 1992PubMedCrossRefGoogle Scholar
  12. Ariad S, Song E, Cohen R, Bezwoda WR. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Molecular Biotherapy 4: 139–142, 1992PubMedCrossRefGoogle Scholar
  13. Ault BH, Stapleton FB, Gaber L, Martin A, Roy III S, et al. Acute renal failure during therapy with recombinant human gamma interferon. New England Journal of Medicine 319: 1397–1400, 1988PubMedCrossRefGoogle Scholar
  14. Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. New England Journal of Medicine 310: 32–35, 1984PubMedCrossRefGoogle Scholar
  15. Ayub A, Zafar M, Al-Harbi A, Ellis M, Qunibi W. Acute renal failure with α-interferon therapy: a case report. Medical Science Research 21: 123–124, 1993Google Scholar
  16. Azar JJ, Theriault RL. Acute cardiomyopathy as a consequence of treatment with interleukin-2 and interferon-alpha in a patient with metastatic carcinoma of the breast. American Journal of Clinical Oncology 14: 530–533, 1991PubMedCrossRefGoogle Scholar
  17. Baer MR, Ozer H, Foon KA. Interferon-α therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. British Journal of Haematology 81: 167–169, 1992PubMedCrossRefGoogle Scholar
  18. Baker BS, Griffiths CEM, Fry L, Valdimarsson H. Psoriasis and interferon. Lancet 2: 342, 1986CrossRefGoogle Scholar
  19. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, et al. The interferons: mechanisms of action and clinical applications. Journal of the American Medical Association 266: 1375–1383, 1991PubMedCrossRefGoogle Scholar
  20. Barreca T, Picciotto A, Franceschini R, Varagona G, Corsini G, et al. Effects of acute administration of recombinant interferon alpha 2b on pituitary hormone secretion in patients with chronic active hepatitis. Current Therapeutic Research 52: 695–701, 1992CrossRefGoogle Scholar
  21. Bauherz G, Soeur M, Lustman F. Oculomotor nerve paralysis induced by alpha II-interferon. Acta Neurologica Belgica 90: 111–114, 1990PubMedGoogle Scholar
  22. Bekisz JB, Zur Nedden DL, Enterline JC, Zoon KC. Antibodies to interferon-alpha 2 for hairy cell leukemia. Journal of Interferon Research 9 (suppl. 1): s1–S7, 1989PubMedGoogle Scholar
  23. Benjamin S, Bain BJ, Dodsworth H. Severe bleeding associated with worsening thrombocytopenia following alpha-interferon therapy for autoimmune thrombocytopenic purpura. Clinical and Laboratory Haematology 13: 315–317, 1991PubMedCrossRefGoogle Scholar
  24. Berglund EF, Burton GV, Mills GM, Nichols GM. Hypertrichosis of the eyelashes associated with interferon-alpha therapy for chronic granulocytic leukemia. Southern Medical Journal 83: 363, 1990PubMedCrossRefGoogle Scholar
  25. Bernsen PLJA, Wong Chung RE, Vingerhoets HM, Janssen JTP. Bilateral neuralgic amyotrophy induced by interferon treatment. Archives of Neurology 45: 449–451, 1988PubMedCrossRefGoogle Scholar
  26. Berris B, Feinman SV. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Digestive Diseases and Sciences 36: 1657–1660, 1991PubMedCrossRefGoogle Scholar
  27. Berruti A, Gorzegno G, Vitetta G, Tampellini M, Dogliotti L. Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report. Tumori 78: 353–355, 1992PubMedGoogle Scholar
  28. Bertini R, Bianchi M, Villa P, Ghezzi P. Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin-1 and tumor necrosis factor: a comparison with lymphotoxin and interferon. International Journal of Immunopharmacology 10: 525–530,. 1988PubMedCrossRefGoogle Scholar
  29. Bevan PC. Interferon-induced parotitis and epididymitis. Lancet 2: 561, 1985PubMedCrossRefGoogle Scholar
  30. Bhakri H, Sriskandan K, Davis T, Pettingale K, Tee D. Recombinant gamma interferon and autoimmune thyroid disease. Lancet 2: 457, 1985PubMedCrossRefGoogle Scholar
  31. Bladé J, Lopez-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. British Journal of Haematology 79: 523–525, 1991PubMedCrossRefGoogle Scholar
  32. Bocci V. Central nervous system toxicity of interferons and other cytokines. Journal of Biological Regulators and Homeostatic Agents 2: 107–118, 1988PubMedGoogle Scholar
  33. Bork K, Bräuninger W, Röhrborn W. Metastases of malignant melanoma due to interferon alpha-2a? Dermatologica 177: 249–250, 1988PubMedCrossRefGoogle Scholar
  34. Born J, Spath-Schwalbe E, Pietrowsky R, Porzsolt F, Fehm HL. Neurophysiological effects of recombinant interferon-gamma and alpha in man. Clinical Physiology and Biochemistry 7: 119–127, 1989PubMedGoogle Scholar
  35. Braathen LR, Stavem P. Autoimmune haemolytic anaemia associated with interferon alpha-2a in patients with mycosis fungoides. British Medical Journal 298: 1713, 1989PubMedCrossRefGoogle Scholar
  36. Burman P, Karlsson FA, Oberg K, Alm G. Autoimmune thyroid disease in interferon-treated patients. Lancet 2: 100–101, 1985CrossRefGoogle Scholar
  37. Burman P, Tötterman TH, Öberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. Journal of Clinical Endocrinology and Metabolism 63: 1086–1090, 1986PubMedCrossRefGoogle Scholar
  38. Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-α for type II essential mixed cryoglobulinemia. Blood 78: 3142–3147, 1991PubMedGoogle Scholar
  39. Catani L, Gugliotta L, Zauli G, Bagnara GP, Antonelli G, et al. In vitro inhibition of interferon alpha-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythaemia. Haematologica 77: 318–321, 1992PubMedGoogle Scholar
  40. Chan GCB, Lee SS, Yeoh EK. Mono-arthritis in a chronic hepatitis B patient after alpha-interferon treatment. Journal of Gastroenterology and Hepatology 7: 432–433, 1992PubMedCrossRefGoogle Scholar
  41. Chazerain P, Meyer O, Ribard P, de Bandt M, Mechelany, et al. Trois cas de polyarthrite survenant au cours d’un traitement par interféron-alpha recombinant. Revue du Rhumatisme et des Maladies Ostéoarticulaires 59: 303–309, 1992Google Scholar
  42. Chowhan NM, Zarrabi MH. Late febrile reaction to interferon. American Journal of Hematology 41: 144, 1992PubMedCrossRefGoogle Scholar
  43. Chung YH, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-α2b for chronic viral hepatitis. American Journal of Gastroenterology 88: 244–247, 1993PubMedGoogle Scholar
  44. Clanet M, Blancher A, Calvas P, Rascol O. Interferons and multiple sclerosis. Biomedicine and Pharmacotherapy 43: 355–360, 1989CrossRefGoogle Scholar
  45. Cnudde F, Gharakhanian S, Luboinski J, Dry J, Rozenbaum W. Cutaneous local necrosis following interferon injections. International Journal of Dermatology 30: 147, 1991PubMedCrossRefGoogle Scholar
  46. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha2 interferon-related cardiomyopathy. American Journal of Medicine 85: 549–551, 1988PubMedCrossRefGoogle Scholar
  47. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65: 2237–2242, 1990PubMedCrossRefGoogle Scholar
  48. Cottier-Fox M, Torrisi J, Spitzer TR, Deeg HJ. Increased toxicity of total body irradiation in patients receiving interferon for leukaemia. Lancet 335: 174, 1990CrossRefGoogle Scholar
  49. Craig PI, Mehta I, Murray M, McDonald D, Äström A, et al. Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. Molecular Pharmacology 38: 313–318, 1990PubMedGoogle Scholar
  50. Craig PI, Murray M, Farrell GC. Interferon suppresses the isoformspecific activities of hepatic cytochrome P450 in female rats. Biochemical Pharmacology 43: 908–910, 1992PubMedCrossRefGoogle Scholar
  51. Craig PI, Williams SJ, Cantrill E, Farrell GC. Rat but not human interferons suppress hepatic oxidative drug metabolism in rats. Gastroenterology 97: 999–1004, 1989PubMedGoogle Scholar
  52. Craxi A, Di Marco V, Volpes R, Palazzo U. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepato-Gastroenterology 35: 304–305, 1988PubMedGoogle Scholar
  53. Crockett DM, Lusk RP, McCabe BF, Mixon JH. Side effects and toxicity of interferon in the treatment of recurrent respiratory papillomatosis. Annals of Otology, Rhinology and Laryngology 96: 601–607, 1987Google Scholar
  54. Crump M, Wang XH, Sermer M, Keating A. Successful pregnancy and delivery during α-interferon therapy for chronic myeloid leukemia. American Journal of Hematology 40: 238–239, 1992PubMedCrossRefGoogle Scholar
  55. Cudillo L, Cantonetti M, Venditti A, Lentini R, Rossini PM, et al. Peripheral polyneuropathy during treatment with alpha-2 interferon. Haematologica 75: 485–486, 1990PubMedGoogle Scholar
  56. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, et al. Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial. Journal of Hepatology 11 (suppl. 1): s31–S35, 1990PubMedCrossRefGoogle Scholar
  57. Desai RG. Drug interaction between alpha interferon and erythropoietin. Journal of Clinical Oncology 9: 893, 1991PubMedGoogle Scholar
  58. Detmar U, Agathos M, Nerl C. Allergy of delayed type to recombinant interferon alpha-2C. Contact Dermatitis 20: 149–150, 1989PubMedCrossRefGoogle Scholar
  59. Deyton LR, Walker RE, Kovacs JA, Herpin B, Parker M, et al. Reversible cardiac dysfunction associated with interferon alpha therapy in AIDS patients with Kaposi’s sarcoma. New England Journal of Medicine 321: 1246–1249, 1989PubMedCrossRefGoogle Scholar
  60. Dianzani F. Interferon treatments: how to use an endogenous system as a therapeutic agents. Journal of Interferon Research (special issue, May 1992): 109–118, 1992Google Scholar
  61. Dianzani F, Antonelli G, Amicucci P, Cefaro A, Pintus C. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients. Journal of Interferon Research 9 (suppl. 1): s33–S36, 1989PubMedGoogle Scholar
  62. Dierckx RA, Michotte A, Schmedding E, Ebinger G, Degeeter T, et al. Unilateral seizures in a patient with hairy cell leukemia treated with interferon. Clinical Neurology and Neurosurgery 87: 209–212, 1985PubMedCrossRefGoogle Scholar
  63. Dixon RM, Borden EC, Keim NL, Anderson S, Spennetta TL, et al. Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferon. Metabolism 33: 400–404, 1984PubMedCrossRefGoogle Scholar
  64. Dorr RT. Interferon-α in malignant and viral diseases. Drugs 45: 177–211, 1993PubMedCrossRefGoogle Scholar
  65. Dreno B, Huart A, Billaud E, Litoux P, Godefroy WY. Alpha-interferon therapy and cutaneous vascular lesions. Annals of Internal Medicine 111: 95–96, 1989PubMedGoogle Scholar
  66. Dumas JC, Giroux M, Teixeira MG, Puel J, Waysbort A, et al. Etude du passage transplacentaire de G interféron alpha-2a sur le modèle du cotylédon isolé perfusé. Thérapie 48: 73–75, 1993PubMedGoogle Scholar
  67. Durand JM, Kaplanski G, Portai I, Scheiner C, Berland Y, et al. Liver failure due to recombinant alpha interferon. Lancet 338: 1268–1269, 1991PubMedCrossRefGoogle Scholar
  68. Echizen H, Ohta Y, Shirataki H, Tsukamoto K, Umeda N, et al. Effects of subchronic treatment with natural interferons on antipyrine clearance and liver function in patients with chronic hepatitis. Gastroenterology 30: 562–567, 1990Google Scholar
  69. Ernstoff MS, Kirkwood JM. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. American Journal of Medicine 76: 593–596, 1984PubMedCrossRefGoogle Scholar
  70. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, et al. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 340: 548, 1992PubMedCrossRefGoogle Scholar
  71. Färkkilä M, Iivanainen M, Roine R, Bergström L, Laaksonen R, et al. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 69: 42–46, 1984Google Scholar
  72. Färkkilä M, Iivanainen M. Thrombocytopenia and interferon. British Medical Journal 296: 642, 1988PubMedCrossRefGoogle Scholar
  73. Färkkilä AM, Iivanainen MV, Färkkilä MA. Disturbance of the water and electrolyte balance during high-dose interferon treatment. Journal of Interferon Research 10: 221–227, 1990PubMedCrossRefGoogle Scholar
  74. Fattovich G, Betterle C, Brollo L, Giustina G, Pedini B, et al. Induction of autoantibodies during alpha interferon treatment in chronic hepatitis B. Archives of Virology 4 (Suppl.): 291–293, 1992aCrossRefGoogle Scholar
  75. Fattovich G, Giustina G, Adami F. Visceral leishmaniasis complicating chronic hepatitis B treated with interferon. Infection 20: 293–294, 1992bPubMedCrossRefGoogle Scholar
  76. Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, et al. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. European Journal of Cancer and Clinical Oncology 24: 1299–1303, 1988CrossRefGoogle Scholar
  77. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1: 1166, 1985PubMedCrossRefGoogle Scholar
  78. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Archives of Dermatology 126: 351–355, 1990PubMedCrossRefGoogle Scholar
  79. Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Seminars in Hematology 25 (Suppl. 3), 9–15, 1988PubMedGoogle Scholar
  80. Finter NB, Chapman S, Dowd P, Johnston JM, Manna V, et al. The use of interferon-α in virus infections. Drugs 42: 749–765, 1991PubMedCrossRefGoogle Scholar
  81. Fonseca V, Thomas M, Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrinologica 125: 491–493, 1991PubMedGoogle Scholar
  82. Foon KA, Dougher G. Increased growth of eyelashes in a patient given leukocyte A interferon. New England Journal of Medicine 311: 1259, 1984PubMedCrossRefGoogle Scholar
  83. Fornaciari G, Bassi C, Beltrami M, Castagnetti E, Maccari S, et al. Hemolytic anemia secondary to interferon treatment for chronic B hepatitis. Journal of Clinical Gastroenterology 13: 596–597, 1991PubMedGoogle Scholar
  84. Friess GG, Brown TD, Wrenn RC. Cardiovascular rhythm effects of gamma recombinant DNA interferon. Investigational New Drugs 7: 275–280, 1989PubMedCrossRefGoogle Scholar
  85. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. British Journal of Dermatology 125: 463–465, 1991PubMedCrossRefGoogle Scholar
  86. Galton JE, Bedford P, Scott JE, Brand CM, Nethersell ABW. Antibodies to lymphoblastoid interferon. Lancet 2: 572–573, 1989PubMedCrossRefGoogle Scholar
  87. Gauci L. Management of cancer patients receving interferon alfa-2a. International Journal of Cancer (Suppl. 1): 21–30, 1987Google Scholar
  88. Gastineau DA, Habermann TM, Hermann RC. Severe neuropathy associated with low-dose recombinant interferon-alpha. American Journal of Medicine 87: 116, 1989PubMedCrossRefGoogle Scholar
  89. Giles FJ, Worman CP, Jewell AP, Goldstone AH. Recombinant alpha-interferons, thyroid irradiation and thyroid disease. Acta Haematologica 85: 160–163, 1991PubMedCrossRefGoogle Scholar
  90. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clinical and Experimental Immunology 90: 363–367; 1992PubMedCrossRefGoogle Scholar
  91. Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, et al. Interferon-a stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 57: 489–495, 1993PubMedCrossRefGoogle Scholar
  92. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, et al. Induction of systemic lupus erythematosus by interferongamma in a patient with rheumatoid arthritis. Journal of Rheumatology 18: 1621–1622, 1991PubMedGoogle Scholar
  93. Grunfeld C, Kotier DP, Shigenaga JK, Doerrler W, Tierney A, et al. Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. American Journal of Medicine 90: 154–162, 1991PubMedGoogle Scholar
  94. Guillot P, Barbuat C, Richard B, Jourdan J. Myocardiopathie réversible induite par l’interféron. Thérapie 48: 65–66, 1993PubMedGoogle Scholar
  95. Guyer DR, Tiedeman J, Yannuzzi LA, Slakter JS, Parke D, et al. Interferon-associated retinopathy. Archives of Ophthalmology 111: 350–356, 1993PubMedCrossRefGoogle Scholar
  96. Hagberg H, Blomkvist E, Ponten U, Persson L, Muhr C, et al. Does alpha-interferon in conjunction with radiotherapy increase the risk of complications in the central nervous system? Annals of Oncology 1: 449, 1990PubMedGoogle Scholar
  97. Harousseau JL, Milpied N, Bourhis JH, Guimbretiere L, Talmant P. Aplasie fatale après traitement par interféron alpha d’une leucémie myéloïde chronique en rechute après greffe de moelle osseuse allogénique. Presse Medicale 17: 80–81, 1988Google Scholar
  98. Harrison PV, Peat MJ. Effect of interferon on psoriasis. Lancet 2: 457–458, 1986PubMedCrossRefGoogle Scholar
  99. Hartmann F, von Wussow P, Deicher H. Psoriasis-Exazerbation bei Therapie mit α-Interferon. Deutsche Medizinische Wochenschrift 114: 96–98, 1989PubMedCrossRefGoogle Scholar
  100. Herrman J, Gabriel F. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon. Lancet 316: 112–113, 1987Google Scholar
  101. Hibi H, Itoh K, Kamiya T, Yamada Y, Shimoji TL. Grand mal like attack by interferon injection in case of renal cell carcinoma. Hinyokika Kiyo 37: 69–72, 1991PubMedGoogle Scholar
  102. Iaffaioli RV, Fiorenza L, D’Avino M, Frasci G, La Mura G, et al. Neurotoxic effects of long-term treatment with low-dose alpha 2B interferon. Current Therapeutic Research 48: 403–408, 1990Google Scholar
  103. Iivanainen M, Laaksonen R, Niemi ML, Färkkilä M, Bergström L, et al. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 72: 475–480, 1985PubMedCrossRefGoogle Scholar
  104. Ijzermans JN, Bouwman E, de Bruin RW, Jeekel J, Marquet RL. Treatment with rIFN-gamma has no effect on cardiac allograft rejection. Immunology 73: 243–245, 1991PubMedGoogle Scholar
  105. Ikeda Y, Miyake K, Toda G, Yamada H, Yamanaka M, et al. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease. Journal of Gastroenterology and Hepatology 4: 411–418, 1989PubMedCrossRefGoogle Scholar
  106. Ikeda Y, Toda G, Hashimoto N, Umeda N, Miyake K, et al. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Clinical and Experimental Immunology 85: 80–84, 1991PubMedCrossRefGoogle Scholar
  107. Itoh S, Matsuo S, Shimoji K, Oda T, Sasaki I, et al. The effect of alpha-interferon on the liver in a patient with hairy cell leukemia: light and electron microscopic studies. American Journal of Gastroenterology 84: 942–947, 1989PubMedGoogle Scholar
  108. Itoh Y, Okanoue T, Enjyo F, Morimoto M, Takeuchi T, et al. Elevated interleukin-6 and γ-globulin during interferon therapy for hepatitis B. American Journal of Gastroenterology 87: 1485–1487, 1992PubMedGoogle Scholar
  109. Itri LM, Sherman MI, Palleroni AV, Evans LM, Tran LL, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. Journal of Interferon Research 9 (suppl. 1): s9–S15, 1989PubMedGoogle Scholar
  110. Jacobs EL, Clare-Salzer MJ, Chopra IJ, Figlin RA. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha. Journal of Immunotherapy 10: 448–455, 1991PubMedCrossRefGoogle Scholar
  111. Jaffe HS, Chen AB, Kramer S, Sherwin SA. The absence of interferon antibody formation in patients receiving recombinant human interferon-gamma. Journal of Biological Response Modifiers 6: 576–580, 1987PubMedGoogle Scholar
  112. Janssen HLA, Berk L, Vermeulen M, Schalm SW. Seizures associated with low-dose alpha-interferon. Lancet 336: 1580, 1990PubMedCrossRefGoogle Scholar
  113. Janssen HLA, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, et al. Fatal hepatic decompensation associated with interferon alfa. Lancet 306: 107–108, 1993Google Scholar
  114. Jaubert D, Hauteville D, Pelissier JF, Muzellec Y. Neuropathie périphérique au cours d’un traitement par interféron alpha. Presse Médicale 20: 221–222, 1991Google Scholar
  115. Javier RM, Sibilia J, Kuntz JL, Schlienger JL, Asch L. Interféron alpha-2b et hypothyroïdie. Revue du Rhumatisme et des Maladies Ostéoarticulaires 59: 501, 1992Google Scholar
  116. Jones GJ, Itri MI. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 57: 1709–1715, 1986PubMedCrossRefGoogle Scholar
  117. Jonkman JHG, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, et al. Effects of alfa-interferon on theophylline pharmacokinetics and metabolism. British Journal of Clinical Pharmacology 27: 795–802, 1989PubMedCrossRefGoogle Scholar
  118. Jucgla A, Marcoval J, Curco N, Servitje O. Psoriasis with articular involvement induced by interferon alfa. Archives of Dermatology 127: 910–911, 1991PubMedCrossRefGoogle Scholar
  119. Kalkner M, Hagberg H, Karlsson-Parra A. Autoantibody occurrence in hairy-cell leukemia during prolonged interferon treatment. European Journal of Haematology 45: 233–234, 1990PubMedCrossRefGoogle Scholar
  120. Kanfer EJ, McCarthy DM. Immune thrombocytopenia and interferon alfa. British Medical Journal 297: 1613, 1988PubMedCrossRefGoogle Scholar
  121. Karlsson-Parra A, Burman P, Hagberg H, Oberg K, Alm G, et al. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha). Clinical and Experimental Immunology 81: 72–75, 1990PubMedCrossRefGoogle Scholar
  122. Katz JA, Mahoney DH, Steuber CP, Fernbach DJ. Human leukocyte alpha interferon-induced transient neurotoxicity in children. Investigational New Drugs 6: 115–120, 1988PubMedCrossRefGoogle Scholar
  123. Kauppila A, Cantell K, Janne O, Kokko E, Vihko R. Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptors levels during administration of human leukocyte interferon. International Journal of Cancer 29: 291–294, 1982CrossRefGoogle Scholar
  124. Kellokumpu-Lehtinen P, Iisalo E, Nordman E. Hepatotoxicity of paracetamol in combination with interferon and vinblastine. Lancet 1: 1143, 1989PubMedCrossRefGoogle Scholar
  125. Klingemann HG, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, et al. Treatment with recombinant interferon (α-2b) early after bone marrow transplantation in patients at high risk for relpase. Blood 78: 3306–3311, 1991PubMedGoogle Scholar
  126. Koehler SM, Glass J. Neurotoxicity of interferon-alpha. Neurology 42: 939, 1992PubMedCrossRefGoogle Scholar
  127. Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, et al. Adverse effect of low-dose prophylactic human recombinant leucocyte interferon-alpha treatment in renal transplant patients. Transplantation 45: 402–405, 1988PubMedCrossRefGoogle Scholar
  128. Kowalzick L, Meyer U. Psoriasis induced at the injection site of recombinant interferons. Archives of Dermatology 126: 1515–1516, 1990PubMedCrossRefGoogle Scholar
  129. Krishnan R, Ellinwood EH, Laszlo J, Hood L, Ritchie J. Effect of gamma interferon on the hypothalamic-pituitary-adrenal system. Biology of Psychiatry 22: 1163–1166, 1987CrossRefGoogle Scholar
  130. Kung AWC, Jones BM, Lai CL. Effects of interferon-gamma therapy on thyroid function, T-lymphocytes subpopulation and induction of autoantobodies. Journal of Clinical Endocrinology and Metabolism 71: 1230–1234, 1990PubMedCrossRefGoogle Scholar
  131. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Renal Failure 13: 87–93, 1991PubMedCrossRefGoogle Scholar
  132. Kurzrock R, Rohde MF, Quesada JR, Gianturco SH, Bradley WA, et al. Recombinant γ interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. Journal of Experimental Medicine 164: 1093–1101, 1986PubMedCrossRefGoogle Scholar
  133. Kusec R, Ostojié S, Planinc-Peraica A, Minigo H, Jasksié B. Exacerbation of psoriasis after treatment with alpha-interferon. Dermatologica 181: 170, 1990PubMedCrossRefGoogle Scholar
  134. Laaksonen R, Niiranen A, Iivanainen M, Mattson K, Holsti L, et al. Dementia-like, largely reversible syndrome after cranial irradiation and prolonged interferon treatment. Annals of Clinical Research 20: 201–203, 1988PubMedGoogle Scholar
  135. Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-βser. Journal of Interferon Research 9 (suppl. 1): s51–S60, 1989PubMedGoogle Scholar
  136. Larrey D, Marcellin P, Fréneaux E, Pessayre D, Benhamou JP. Exacerbation of multiple sclerosis after the administration of recombinant human interferon alpha. Journal of the American Medical Association 261: 2065, 1989PubMedCrossRefGoogle Scholar
  137. Laskus T, Radkowski M, Slusarczyk J, Cianciara J. Severe exacerbation of chronic active hepatitis B during interferon alpha therapy. Digestion 52: 61–64, 1992PubMedCrossRefGoogle Scholar
  138. Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon alpha. American Journal of Kidney Diseases 20: 516–518, 1992PubMedGoogle Scholar
  139. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. American Journal of Gastroenterology 88: 760–761, 1993PubMedGoogle Scholar
  140. Liberati AM, Biagini S, Perticoni G, Ricci S, D’Alessandro P, et al. Electrophysiological and neuropsychological functions in patients treated with interferon-beta. Journal of Interferon Research 10: 613–619, 1990PubMedCrossRefGoogle Scholar
  141. Liet JM, Casasnovas RO, Terraz A, Caillot D, Petrella T, et al. Acute leucocytoclastic vascularitis with IgA deposits during interferon alpha treatment. Revue de Médecine Interne 13 (suppl. 6): 169, 1992CrossRefGoogle Scholar
  142. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102: 2155–2160, 1992PubMedGoogle Scholar
  143. Lok ASF, Lai CL, Leung EKY. Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12: 1266–1270, 1990PubMedCrossRefGoogle Scholar
  144. Lopez Morante AJ, Saez-Royuela F, Casanova Valero F, Yeguero del Moral L, Martin Lorente JL, et al. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C. American Journal of Gastroenterology 87: 809–810, 1992PubMedGoogle Scholar
  145. Maccari S, Bassi C, Giovannini AG, Lancher AC. A case of arthropathy and hypothyroidism during recombinant alpha-interferon therapy. Clinical Rheumatology 10: 452–454, 1991PubMedCrossRefGoogle Scholar
  146. Machold KP, Smolen JS. Interferon-gamma induced exacerbation of systemic lupus erythematosus. Journal of Rheumatology 17: 831–832, 1990PubMedGoogle Scholar
  147. Mangan KF, Zidar B, Shadduck RK, Zeigler Z, Winkelstein A. Interferon-induced aplasia: evidence for T-cell-mediated suppression of hematopoiesis and recovery after treatment with horse antihuman thymocyte globulin. American Journal of Hematology 19: 401–413, 1985PubMedCrossRefGoogle Scholar
  148. Mannering GJ, Deloria LB. The pharmacology and toxicology of the interferons: an overview. Annual Review of Pharmacology and Toxicology 26: 455–515, 1986PubMedCrossRefGoogle Scholar
  149. Mansat-Krzyzanowska E, Dréno B, Chiffoleau A, Litoux P. Manifestations cardio-vasculaires associées à l’interféron α-2a. Annales de Médecine Interne 142: 576–581, 1991PubMedGoogle Scholar
  150. Marcellin P, Colin JF, Boyer N, Bernuau J, Degott C, et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alphainterferon. Lancet 338: 828, 1991PubMedCrossRefGoogle Scholar
  151. Marcellin P, Pouteau M, Renard P, Grynblat JM, Colas Linhart N, et al. Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 33: 855–856, 1992PubMedCrossRefGoogle Scholar
  152. Martino S, Ratanatharathorn V, Karanes C, Samal BA, Sohn YH, et al. Reversible arrhythmias observed in patients treated with recombinant alpha2 interferon. Journal of Cancer Research and Clinical Oncology 113: 376–378, 1987PubMedCrossRefGoogle Scholar
  153. Massaro ER, Borden EC, Hawkins MJ, Wiebe DA, Shrago E. Effects of recombinant interferon-α2 treatment upon lipid concentrations and lipoprotein composition. Journal of Interferon Research 6: 665–662, 1986CrossRefGoogle Scholar
  154. Matsumura S, Takamatsu H, Ara S. Central nervous system toxicity of local interferon-β therapy. Neurologia Medico Chirurgica 28: 265–270, 1988PubMedCrossRefGoogle Scholar
  155. Matthey F, Ardeman S, Jones L, Newland AC. Bleeding in immune thrombocytopenic purpura after alpha-interferon. Lancet 335: 471–472, 1990PubMedCrossRefGoogle Scholar
  156. Mattson K, Niiranen A, Iivanainen M, Färkkilä M, Bergström L, et al. Neurotoxicity of interferon. Cancer Treatment Report 67: 958–961, 1983Google Scholar
  157. Mattson K, Niiranen A, Laaksonen R, Cantell K. Psychometric monitoring of interferon neurotoxicity. Lancet 1: 275–276, 1984PubMedCrossRefGoogle Scholar
  158. Mattson K, Niiranen A, Pyrhonen S, Farkkila M, Cantell K. Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity. Acta Oncologica 30: 607–610, 1991PubMedCrossRefGoogle Scholar
  159. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, et al. Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10: 24–28, 1989PubMedCrossRefGoogle Scholar
  160. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. Lancet 2: 1175–1177, 1987PubMedCrossRefGoogle Scholar
  161. McLaughlin P, Talpaz M, Quesada JR, Saleem A, Barlogie B. Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. Journal of the American Medical Association 253: 1353–1354, 1985CrossRefGoogle Scholar
  162. McNair ANB, Jacyna MR, Thomas HC. Severe haemolytic transfusion reaction occurring during alpha-interferon therapy for chronic hepatitis. European Journal of Gastroenterology and Hepatology 3: 193–194, 1991Google Scholar
  163. Meadows LM, Walther P, Ozer H. α-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. Seminars in Oncology 18 (suppl. 7): 71–76, 1991PubMedGoogle Scholar
  164. Mehta ND, Hooberman AL, Vokes EE, Neeley S, Cotler S. 35-yearold patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy. American Journal of Hematology 41: 141, 1992PubMedCrossRefGoogle Scholar
  165. Merimsky O, Nisipeanu P, Loewenstein A, Reider-Groswasser I, Chaitchik S. Interferon-related cortical blindness. Cancer Chemotherapy and Pharmacology 29: 329–330, 1992PubMedCrossRefGoogle Scholar
  166. Merimsky O, Reider I, Merimsky E, Chaitchik S. Interferon-related leukoencephalopathy in a patient with renal cell carcinoma. Tumori 77: 361–362, 1991PubMedGoogle Scholar
  167. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferonrelated mental deterioration and behavioural changes in patients with renal cell carcinoma. European Journal of Cancer 26: 596–600, 1990PubMedCrossRefGoogle Scholar
  168. Meyers CA, Obbens EA, Scheibel RS, Moser RP. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68: 88–92, 1991aPubMedCrossRefGoogle Scholar
  169. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41: 672–676, 1991bPubMedCrossRefGoogle Scholar
  170. Meyers JD, Flournoy N, Sandus JE, McGuffin RW, Newton BA, et al. Prophylactic use of human leucocyte interferon after allogeneic bone marrow transplantation. Annals of Internal Medicine 107: 809–816, 1987PubMedGoogle Scholar
  171. Mirro J, Kalwinsky D, Whisnant J, Weck P, Chesney C, et al. Coagulopathy induced by continuous infusion of high doses of human lymphoblastoid interferon. Cancer Treatment Report 69: 315–317, 1985Google Scholar
  172. Moraleda JM, Gonzalez R, Alegre A, Anta JP, San Miguel JF. Bone marrow necrosis and treatment with interferon. Journal of Clinical Pathology 39: 1045, 1986PubMedCrossRefGoogle Scholar
  173. Müller H, Hiemke C, Hammes E, Hess G. Sub-acute effects of interferon-α2 on adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in humans. Psychoneuroendocrinology 17: 459–465, 1992PubMedCrossRefGoogle Scholar
  174. Nair S, Ernstoff MS, Bahnson RR, Arthur S, Johnston J, et al. Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology 39: 169–172, 1992PubMedCrossRefGoogle Scholar
  175. Newton RC. Effect of interferon on the induction of human monocyte secretion of interleukin-1 activity. Immunology 56: 441–445, 1985PubMedGoogle Scholar
  176. Niiranen A, Laaksonen R, Iivanainen M, Mattson K, Farkkila M, et al. Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatrica Scandinavica 78: 622–626, 1988PubMedCrossRefGoogle Scholar
  177. Noël C, Vrtovsnik F, Facon T, Noel-Walter MP, Hazzan M, et al. Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: report on two patients. American Journal of Hematology 41: 298–299, 1992PubMedCrossRefGoogle Scholar
  178. O’Connell PG, Gerber LH, DiGiovanna JJ, Peck GL. Arthritis in patients with psoriasis treated with gamma-interferon. Journal of Rheumatology 19: 80–82, 1992PubMedGoogle Scholar
  179. Oberg KE. Development of an SLE syndrome in a patient with malignant carcinoid tumor after treatment with alpha interferon. Interferons and Cytokines 12: 30–32, 1989Google Scholar
  180. Oberg KE, Alm G, Magnusson A, Lundqvist G, Theodorsson E, et al. Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. Journal of the National Cancer Institute 81: 531–535, 1989PubMedCrossRefGoogle Scholar
  181. Oberg KE, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncologica 28: 425–431, 1989PubMedCrossRefGoogle Scholar
  182. Okuno H, Kitao Y, Takasu M, Kano H, Kunieda K, et al. Depression of drug-metabolizing activity in the human liver by interferon-alpha. European Journal of Clinical Pharmacology 39: 365–367, 1990PubMedCrossRefGoogle Scholar
  183. Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, et al. Depression of drug-metabolizing activity in the human liver by interferonbeta. Hepatology 17: 65–69, 1993PubMedCrossRefGoogle Scholar
  184. Orlow SJ, Friedman-Kein AE. Cutaneous ulcerations secondary to interferon alfa therapy of Kaposi’s sarcoma. Archives of Dermatology 128: 566, 1992PubMedCrossRefGoogle Scholar
  185. Ornellas de Souza MH, Abdelhay E, Silva MLM, Diamond HR, Valente AN, et al. Late marrow allograft rejection following alpha-interferon therapy for hepatitis in a patient with paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplantation 9: 495–497, 1992Google Scholar
  186. Osterborg A, Engman K, Bjoreman M, Carlson K, Kimby E, et al. Patients treated with natural (leukocyte-derived) interferon (IFN)-alpha do not develop IFN antibodies. European Journal of Haematology 47: 234–235, 1991PubMedCrossRefGoogle Scholar
  187. Pagliacci MC, Pelicci G, Schippa M, Liberati AM, Nicoletti I. Does interferon-beta therapy induce thyroid autoimmune phenomena? Hormal and Metabolic Research 23: 196–197, 1991CrossRefGoogle Scholar
  188. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37: 1097–1102, 1987PubMedCrossRefGoogle Scholar
  189. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Annals of Internal Medicine 116: 51–53, 1992aPubMedGoogle Scholar
  190. Papo T, Oksenhendler E, Izembart M, Leger A, Clauvel JP. Antithyroid hormone antibodies induced by interferon-α. Journal of Clinical Endocrinology and Metabolism 75: 1484–1486, 1992bPubMedCrossRefGoogle Scholar
  191. Pardini S, Bosincu L, Bonfilgi S, Dore F, Longinotti M. Anaphylactic-like syndrom in systemic mastocytosis treated with alpha-2-interferon. Acta Haematologica 85: 220, 1991PubMedCrossRefGoogle Scholar
  192. Parodi A, Semino M, Gallo R, Rebora A. Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 186: 155–157, 1993PubMedCrossRefGoogle Scholar
  193. Pavord S, Sivakumaran M, Durrant S, Chapman C. The role of alpha interferon in the pathogenesis of GVHD. Bone Marrow Transplantation 10: 477, 1992PubMedGoogle Scholar
  194. Pecorari P. Colite ulcerosa in corso di leucemia a cellule capellute. Descrizione di un caso. Recenti Progressi in Medicina 82: 269–271, 1991Google Scholar
  195. Pende A, Musso NR, Vergassola C, Puppo F, Ioverno A, et al. Neuroendocrine effects of interferon alpha 2-a in healthy human subjects. Journal of Biological Regulators and Homeostatic Agents 4: 67–72, 1990PubMedGoogle Scholar
  196. Perez R, Padavic K, Krigel R, Weiner L. Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon. Cancer 67: 2512–2517, 1991PubMedCrossRefGoogle Scholar
  197. Petit JJ, Callis M, Fernandez de Sevilla A. Normal pregnancy in a patient with essential thrombocythemia treated with interferon-α2b. American Journal of Hematology 40: 80, 1992PubMedCrossRefGoogle Scholar
  198. Pichert G, Jost LM, Zöbeli L, Odermatt B, Pedio G, et al. Thyroiditis after treatment with interleukine-2 and interferon alpha-2a. British Journal of Cancer 62: 100–104, 1990PubMedCrossRefGoogle Scholar
  199. Pigatto PD, Bigardi A, Legori A, Altomare GF, Riboldi A. Allergic contact dermatitis from beta-interferon in eyedrops. Contact Dermatitis 25: 199–200, 1991PubMedCrossRefGoogle Scholar
  200. Poires JC, Carreno V, Ruiz M, Marron JA, Bartolomé J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. Journal of Hepatology 8: 351–357, 1989CrossRefGoogle Scholar
  201. Prasad S, Waters B, Hill PB, Portera FA, Riely CA. Psychiatric side effects of interferon alpha-2b in patients treated for hepatitis C. Abstract. Clinical Research 40: 840A, 1992Google Scholar
  202. Prümmer O, Seyfarth C, Scherbaum WA, Drees N, Porzsolt F. Interferon-alpha antibodies in autoimmune diseases. Journal of Interferon Research 9 (suppl. 1): s67–S74, 1989PubMedGoogle Scholar
  203. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1: 1466–1468, 1986PubMedCrossRefGoogle Scholar
  204. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. Journal of Clinical Oncology 4: 234–243, 1986PubMedGoogle Scholar
  205. Rabinowitz AP, Hu E, Watkins K, Mazumder A. Hemolytic anemia in a cancer patient treated with recombinant interferon-gamma. Journal of Biological Response Modifiers 9: 256–259, 1990PubMedGoogle Scholar
  206. Rasokat H, Bendick C, Wemmer U, Steigleder GK. Aseptische Hautnekrose nach subkutaner Injektion von Interferon-alpha. Deutsche Medizinische Wochenschrift 114: 458–460, 1989PubMedCrossRefGoogle Scholar
  207. Reichel RP, Linkesch W, Schetitska D. Therapy with recombinant interferon alpha-2c during unexpected pregnancy in a patient with chronic myeloid leukaemia. British Journal of Haematology 82: 472–473, 1992PubMedCrossRefGoogle Scholar
  208. Reid I, Sharpe I, McDevitt J, Maxwell W, Emmons R, et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. British Journal of Cancer 64: 915–918, 1991PubMedCrossRefGoogle Scholar
  209. Reid III TJ, Lombardo FA, Redmond III J, Hammond SL, Coffey JA, et al. Digital vasculitis associated with interferon therapy. American Journal of Medicine 92: 702–703, 1992PubMedCrossRefGoogle Scholar
  210. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Seminars in Liver Disease 9: 273–277, 1989PubMedCrossRefGoogle Scholar
  211. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, et al. Psychiatric complications of long-term interferon alpha therapy. Archives of Internal Medicine 147: 1577–1580, 1987PubMedCrossRefGoogle Scholar
  212. Renton KW, Singh G, Stebbing N. Relationship between the antiviral effects of interferons and their abilities to depress cytochrome P-450. Biochemical Pharmacology 33: 3899–3902, 1984PubMedCrossRefGoogle Scholar
  213. Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, et al. Central nervous system toxicity of interferon. British Journal of Cancer 47: 419–422, 1983PubMedCrossRefGoogle Scholar
  214. Rönnblom LE, Alm GV, Öberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. Journal of Internal Medicine 227: 207–210, 1990PubMedCrossRefGoogle Scholar
  215. Rönnblom LE, Alm GV, Öberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Annals of Internal Medicine 115: 178–183, 1991PubMedGoogle Scholar
  216. Rosenzweig IB, Wiebe DA, Borden EC, Storer B, Shago ES. Plasma lipoproteins changes in humans induced by β-interferon. Atherosclerosis 67: 261–267, 1987PubMedCrossRefGoogle Scholar
  217. Rossetti F, Pontini F, Crivallaro C, Cadrobbi P, Guido M, et al. Interferon therapy of chronic delta-hepatitis in a patient cured of pediatric malignancies — possible harmful effect. Liver 11: 255–259, 1991PubMedGoogle Scholar
  218. Roy V, Newland AC. Raynaud’s phenomenon and cryoglobulinaemia associated with the use of recombinant human alpha-interferon. Lancet 1: 944–945, 1988PubMedCrossRefGoogle Scholar
  219. Ruiz-Moreno M, Carreno V, Rua MJ, Cotonat T, Serrano B, et al. Increase in triglycerides during α-interferon treatment of chronic viral hepatitis. Journal of Hepatology 16: 384–388, 1992PubMedCrossRefGoogle Scholar
  220. Russo D, Zuffa E, Bandini G, Baccarani M, Tura S. Mental depression, acute infection and coma in a patient treated with interferon-α. Haematologica 74: 228, 1989PubMedGoogle Scholar
  221. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon-γ induces erythema nodosum leprosum in lepromatous leprosy patients. Journal of Experimental Medicine 175: 1729–1737, 1992PubMedCrossRefGoogle Scholar
  222. Sangster G, Kaye SB, Calman KC, Toy JL. Cutaneous vasculitis associated with interferon. European Journal of Cancer and Clinical Oncology 19: 1647–1649, 1983CrossRefGoogle Scholar
  223. Sauter NP, Atkins MB, Mier JW, Lechan RM. Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report. American Journal of Medicine 92: 441–444, 1992PubMedCrossRefGoogle Scholar
  224. Sawamura M, Matsushima T, Tamura J, Murakami H, Tsuchiya J. Renal toxicity in long-term alpha-interferon treatment in a patient with myeloma. American Journal of Hematology 41: 146, 1992aPubMedCrossRefGoogle Scholar
  225. Sawamura M, Murayama K, Ui G, Matsushima T, Tamura J, et al. Plasma cell leukaemia with alpha-interferon therapy in myeloma. British Journal of Haematology 82: 631, 1992bPubMedCrossRefGoogle Scholar
  226. Scalzo S, Gengaro A, Boccoli G, Masciulli R, Giannella G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. European Journal of Cancer 26: 1152–1156, 1990PubMedCrossRefGoogle Scholar
  227. Schattner A. Interferons and autoimmunity. American Journal of Medical Sciences 295: 532–544, 1988CrossRefGoogle Scholar
  228. Schechter D, Nagler A, Ackerstein A, Nassar H, Admon D, et al. Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. Cardiology 80: 168–171, 1992PubMedCrossRefGoogle Scholar
  229. Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH. The effect of interferon on the metabolism of LDLs. Arteriosclerosis and Thrombosis 12: 1053–1062, 1992PubMedCrossRefGoogle Scholar
  230. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68: 1536–1537, 1991PubMedCrossRefGoogle Scholar
  231. Schilsky RL, Davidson HS, Magid D, Daiter S, Golomb HM. Gonadal and sexual function in male patients with hairy cell leukemia: lack of adverse effects of recombinant alpha 2-interferon treatment. Cancer Treatment Report 71: 179–181, 1987Google Scholar
  232. Schüller J, Czejka MJ, Schernthaner G, Fogl U, Jäger W, et al. Influence of interferon alpha-2b with or without folinic acid on pharmacokinetics of fluorouracil. Seminars in Oncology 19 (suppl. 3): 93–97, 1992PubMedGoogle Scholar
  233. Schultz M, Müller R, von zur Mühlen A, Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet 1: 1452, 1989PubMedCrossRefGoogle Scholar
  234. Seiz M, Kranke M, Kirchner H. Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with recombinant human gamma interferon. Annals of Rheumatic Disease 47: 642–644, 1988CrossRefGoogle Scholar
  235. Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. British Medical Journal 290: 1180, 1985PubMedCrossRefGoogle Scholar
  236. Sheldofsky SI, Swim AT, Robinson JM, Gallicchio VS, Cohen DA, et al. Interleukin-1 depresses cytochrome P450 levels and activities in mice. Life Sciences 40: 2331–2336, 1987CrossRefGoogle Scholar
  237. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 102: 1406–1408, 1992PubMedGoogle Scholar
  238. Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis? Gastroenterology 101: 840–842, 1991PubMedGoogle Scholar
  239. Simone G, Iaffaioli VR, La Mura G, D’Avino M, Costantino G, et al. Reversible heart failure in a non-Hodgkin lymphoma patient being treated with alpha-interferon. Current Therapeutic Research 44: 78–85, 1988Google Scholar
  240. Smedley H, Katrak M, Sikora K, Wheeler T. Neurological effects of recombinant human interferon. British Medical Journal 286: 262–264, 1983PubMedCrossRefGoogle Scholar
  241. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. British Medical Journal 300: 1174–1175, 1990PubMedCrossRefGoogle Scholar
  242. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 99: 557–561, 1991Google Scholar
  243. Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 68: 1538–1544, 1991PubMedCrossRefGoogle Scholar
  244. Spiegel RJ. The alpha interferons: clinical overview. Seminars in Oncology 14 (suppl. 2): 1–12, 1987PubMedGoogle Scholar
  245. Spiegel RJ, Jacobs SL, Treuhaft MW. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. Journal of Interferon Research 9 (suppl. 1): s17–S24, 1989PubMedGoogle Scholar
  246. Spiegel RJ, Spicehandler JR, Jacobs SL, Oden E. Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon (Intron A). American Journal of Medicine 80: 223–228, 1986PubMedCrossRefGoogle Scholar
  247. Sriskandan K, Tee DE, Pettingale KW. Nephrotic syndrome during treatment with interferon. British Medical Journal 290: 1590–1591, 1985PubMedCrossRefGoogle Scholar
  248. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM et al. Resistance to recombinant interferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. New England Journal of Medicine 318: 1409–1413, 1988PubMedCrossRefGoogle Scholar
  249. Steis RG, VanderMolen LA, Lawrence J, Sing G, Ruscetti F, et al. Erythrocytosis in hairy cell leukaemia following therapy with interferon-alpha. British Journal of Haematology 75: 133–135, 1990PubMedCrossRefGoogle Scholar
  250. Stuart-Harris RC, Lauchlan R, Day R. The clinical application of the interferons: a review. Medical Journal of Australia 156: 869–872, 1992PubMedGoogle Scholar
  251. Suter CC, Westmoreland BF, Sharbrough FW, Hermann RC. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clinic Proceedings 59: 847–850, 1984PubMedGoogle Scholar
  252. Talpaz M, Kantarjian H, Zurzrock R, Gutterman JU. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukaemia. Cancer 69: 410–412, 1992PubMedCrossRefGoogle Scholar
  253. Taniguchi Y, Murakami T, Nakanishi K, Tamai M, Matsuura B, et al. Two cases of hypothyroidism associated with alpha-interferon therapy. Internal Medicine 31: 373–376, 1992PubMedCrossRefGoogle Scholar
  254. Teichmann JV, Sieber G, Ludwig WD, Ruehl H. Immunosuppressive effects of recombinant interferon-α during long-term treatment of cancer patients. Cancer 63: 1990–1993, 1989PubMedCrossRefGoogle Scholar
  255. Todd PA, Goa KL. Interferon gamma-1b: a review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 43: 111–122, 1992PubMedCrossRefGoogle Scholar
  256. Tolaymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C, et al. Systemic lupus erythematosus in a child receiving long-term interferon therapy. Journal of Pediatrics 120: 429–432, 1992PubMedCrossRefGoogle Scholar
  257. Tosti A, Misciali C, Bardazzi F, Fanti PA, Varotti C. Telogen effluvium due to recombinant interferon alpha-2b. Dermatology 184: 124–125, 1992PubMedCrossRefGoogle Scholar
  258. Tran A, Beusnel C, Montoya ML, Lussiez V, Hébuterne X, et al. Hépatite auto-immune de type 1 révélée par un traitement par interféron. Gastroentérologie Clinique et Biologique 16: 722–723, 1992PubMedGoogle Scholar
  259. Ueki K, Tsuchida A, Murakami H, Yano S, Kobayashi N, et al. Hypoparathyroidism during alpha-INF therapy in a patient with multiple myeloma. Journal of Medicine 20: 391–397, 1989PubMedGoogle Scholar
  260. Ueno Y, Sohma T. Alpha-interferon-induced nodular rheumatoid arthritis in renal cell carcinoma. Annals of Internal Medicine 117: 266–267, 1992PubMedGoogle Scholar
  261. Vallbracht A, Treuner J, Flehmig B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289: 496–497, 1981PubMedCrossRefGoogle Scholar
  262. Vassiliadis S, Athanassakis I. Type II interferon may be a potential hazardous therapeutic agent during pregnancy. British Journal of Haematology 82: 782–783, 1992PubMedCrossRefGoogle Scholar
  263. Vento S, Di Perri G, Garofano T, Cosco L, Concia E, et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 2: 926, 1989PubMedCrossRefGoogle Scholar
  264. Vesikari T, Nuutila A, Cantel K. Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatrica Scandinavica 77: 619–622, 1988PubMedCrossRefGoogle Scholar
  265. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Safety 7: 417–433, 1992PubMedCrossRefGoogle Scholar
  266. Visco G, Boumis E, Noto P, Comandini UV. Prevention of side-effects of interferon. Lancet 337: 741, 1991PubMedCrossRefGoogle Scholar
  267. Volz MA, Kirkpatrick CH. Interferons 1992. How much of the promise has been realised? Drugs 43: 285–294, 1992PubMedCrossRefGoogle Scholar
  268. Von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, et al. Clinical significance of anti-IFN-a antibody titres during interferon therapy. Lancet 2: 635–636, 1987CrossRefGoogle Scholar
  269. Von Wussow P, Jakschies D, Freund M, Deicher H. Humoral response to recombinant interferon-α2b in patients receiving recombinant interferon-α2b therapy. Journal of Interferon Research 9 (suppl. 1): s25–S31, 1989Google Scholar
  270. Wandl UB, Kloke O, Niederle N. Liver failure due to recombinant alpha interferon for chronic myelogenous leukaemia. Lancet 339: 123–124, 1992aPubMedCrossRefGoogle Scholar
  271. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clinical Immunology and Immunopathology 65: 70–74, 1992bPubMedCrossRefGoogle Scholar
  272. Warrell RP Jr. Retinoid resistance. Lancet 341: 126, 1993PubMedCrossRefGoogle Scholar
  273. Weck PK, Leventhal BG, Brand C, Finter NB. Detection and incidence of neutralizing antibodies to interferon-alpha-n1. Journal of Interferon Research 9 (suppl. 1): s37–S43, 1989PubMedGoogle Scholar
  274. Weiss KS. Nephrotic range of proteinuria and interferon therapy. Annals of Internal Medicine 116: 347, 1992PubMedGoogle Scholar
  275. Wiedermann CJ, Vogel W, Tilg H, Wiedermann FJ, Herold M, et al. Suppression of thyroid function by interferon-alpha2 in man. Naunyn-Schmiedeberg’s Archives of Pharmacology 343: 665–668, 1991PubMedGoogle Scholar
  276. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 2: 939–941, 1987PubMedCrossRefGoogle Scholar
  277. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. British Journal of Clinical Pharmacology 22: 610–612, 1986PubMedCrossRefGoogle Scholar
  278. Williams SJ, Farrell GC. Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity. Hepatology 10: 192–197, 1989PubMedCrossRefGoogle Scholar
  279. Wills RJ. Clinical pharmacokinetics of interferons. Clinical Pharmacokinetics 19: 390–399, 1990PubMedCrossRefGoogle Scholar
  280. Wiselka MJ, Nicholson KG, Kent J, Cookson JB, Tyrrell DAJ. Prophylactic intranasal a2 interferon and viral exacerbations of chronic respiratory disease. Thorax 46: 706–711, 1991PubMedCrossRefGoogle Scholar
  281. Witter FR, Woods AS, Griffin MD, Smith CR, Nadler P, et al. Effects of prednisone, aspirin, and acetaminophen on an in vivo biologic response to interferon in human. Clinical Pharmacology and Therapeutics 44: 239–243, 1988PubMedCrossRefGoogle Scholar
  282. Zbinden G. Effects of recombinant human alpha-interferon in a rodent cardiotoxicity model. Toxicology Letters 50: 25–35, 1990PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Thierry Vial
    • 1
  • Jacques Descotes
    • 1
  1. 1.Laboratoire d’Immunotoxicologie Fondamentale et CliniqueINSERM U80, Faculté de Médecine A. CarrelLyonFrance

Personalised recommendations